Dr. Steven H. Gillis is Chairman at Nohla Therapeutics, Inc., Chairman at VBI Vaccines, Inc., Chairman at Faraday Pharmaceuticals, Inc., Chairman at PhaseRx, Inc., a Managing Director at ARCH Venture Partners LLC, Chairman at Codiak BioSciences, Inc., Chairman at Lycera Corp., Chairman at Scion Pharmaceuticals, Inc., Chairman at Theraclone Sciences, Inc., Chairman at XORI Corp., a Director at Accelerator Corp. and Investment Committee Member at W Fund Management LLC.
He is on the Board of Directors at Pulmatrix, Inc., Shire Plc, bluebird bio, Inc., Allozyne, Inc., Acylin Therapeutics, Inc., AgriGenesis Biosciences Ltd., Biogenesis Ltd., Egenesis, Inc., Homology Medicines, Inc., Just Biotherapeutics, Inc., Lodo Therapeutics Corp., Nexgenia, Inc., OncoResponse, Inc., Petra Pharma Corp. and VentiRx Pharmaceuticals, Inc.
Dr. Gillis was previously employed as Chairman by VBI Vaccines, Inc. /Old/, Executive Chairman, President & CEO by Trubion Pharmaceuticals, Inc., Chairman & Chief Executive Officer by Corixa Corp., Independent Non-Executive Director by Genesis Research & Development Corp. Ltd., Chairman & Chief Executive Officer by Immunex Corp., Chairman by Qwell Pharmaceuticals, Inc., and Executive Chairman by Viral Logic Systems Technology Corp.
He also served on the board at MIGENIX, Inc., Celdara Medical LLC, Groove Biopharma Corp., Limerick BioPharma, Inc., Oncofactor Corp., PPD Dermatology LLC, Pulmatrix Operating Co., Inc., Surface Logix, Inc. and Variation Biotechnologies (US), Inc.
He received his undergraduate degree from Williams College and a doctorate degree from Dartmouth College.